The Muscular Dystrophy Association (MDA) and the ALS Association teamed up to fund a research project with a goal to find a potential therapy for amyotrophic lateral sclerosis (ALS or Lou Gehrig’sDisease). Both associations are nonprofit institutions committed to find cures and treatments for ALS, and to provide services to…
News
A professor at Boston University School of Medicine (BUSM), Carmela Abraham, PhD, recently received one of six Massachusetts Neuroscience Consortium Awards for 2014. Among 60 applications, her work on multiple sclerosis and the role of Klotho, a life extension protein, in the repair of white matter in the disease was selected…
The ALS Association recently announced that three new grants are being awarded to address unmet needs regarding the clinical management of amyotrophic lateral sclerosis (ALS). These funds will support research to benefit both ALS patients and caregivers by reducing unwanted weight loss in these patients, advancing techniques to improve their…
BrainStorm Cell Therapeutics Inc. will be holding a conference call and webcast session to discuss data regarding the company’s phase 2a clinical trial of NurOwn™ for amyotrophic lateral sclerosis (ALS). BrainStorm is a leading biotechnology company in the ALS space that is developing adult stem cell technologies to address neurodegenerative…
News
Israel’s OCS Awards $1.1 Million To BrainStorm Cell Therapeutics For Amyotrophic Lateral Sclerosis
BrainStorm Cell Therapeutics Inc. received nearly $1.1 million in funding from Israel’s Office of the Chief Scientist (OCS) to support the development of NurOwn™, BrainStorm’s therapeutic platform for treating neurodegenerative diseases such as amyotrophic lateral sclerosis (ALS). BrainStorm is a biotechnology company dedicated to the development of innovative adult…
The pathogenesis of amyotrophic lateral sclerosis (ALS) is still not very well understood. A new study on the genetic origin of ALS entitled “Antisense Proline-Arginine RAN Dipeptides Linked to C9ORF72-ALS/FTD Form Toxic Nuclear Aggregates that Initiate In Vitro and In Vivo Neuronal Death” was published in the Journal…
The ALS Association announced that $326,662 will be used to fund new Amyotrophic Lateral Sclerosis (ALS) research. The new funding will seek to expand ongoing research projects to increase the knowledge of the most frequent genetic cause of the disease and support clinical trials dedicated to those that carry…
Yumanity Therapeutics, a new biotechnology company working on the development of drug discoveries for the treatment of conditions caused by protein misfolding, was launched last Monday by well-known leader in the biotech industry Tony Coles, M.D., who is not only the founding investor of the company, but will also serve as its chairman and chief…
A new study entitled “Aggregation propensities of Superoxide Dismutase G93 hotspot mutants mirror Amyotrophic Lateral Sclerosis clinical phenotypes” identified a mechanism that leads to the aggregation of SOD protein mutant forms that are typically found in Amyotrophic lateral sclerosis (ALS) motor neurons. The study opens new therapeutic avenues…
Chemists from Cornell University, using a technique that illuminates very subtle changes in individual proteins, may have found new evidence about the underlying causes of Amyotrophic Lateral Sclerosis (ALS). Professor of chemical biology and chemistry Brian Crane led a study and co-authored a follow-up based on a spectroscopic method that is…
Recent Posts
- Brainstorm leaders urge FDA to update treatment review process
- New ALS research effort aims to speed search for treatments
- The conclusions I reach when I imagine life without ALS
- FDA grants orphan status to new ALS drug candidate PAS-004
- Living simply with ALS means taking it one absurdity at a time